European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib

Xeljanz(®) (tofacitinib) is an oral small-molecule inhibitor that reversibly inhibits Janus-activated kinase (JAK)-dependent cytokine signaling, thus reducing inflammation. As a result of these mechanisms, effects on the immune system such as a moderate decrease in the total lymphocyte count, a dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawalec, Paweł, Śladowska, Katarzyna, Malinowska-Lipień, Iwona, Brzostek, Tomasz, Kózka, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743127/
https://www.ncbi.nlm.nih.gov/pubmed/29317823
http://dx.doi.org/10.2147/TCRM.S138677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743127/
https://www.ncbi.nlm.nih.gov/pubmed/29317823
http://dx.doi.org/10.2147/TCRM.S138677

Ejemplares similares